Zalgen Labs is a privately held Maryland Limited Liability Corporation. Established by co-founders Dr. Luis Branco and Dr. Robert Garry in 2011, Zalgen has built a team of skilled and experienced scientists focusing on basic science and product development for the improvement of humankind. At Zalgen, we treat our customers, employees and patients who benefit from our products with the highest level of respect and admiration.
Managing Director and Co-Founder
Chief Scientific Advisor and Co-Founder
Director of Diagnostics Development
Zalgen integrates passion for discoveries and advancement in the biological sciences with uncompromising commitment toward fulfilling diagnostic, preventive, and therapeutic solutions for unmet and underrepresented medical needs worldwide, through excellence, nobility, proven execution, and innovation.
Young patient being tested for Lassa fever with ReLASV Antigen Rapid Test. Kenema Government Hospital, Kenema, Sierra Leone. (2009) Photo courtesy L Branco
Zalgen Labs is a biotechnology company founded in 2011, specializing in the design and production of superior biological molecules critical for the development and commercialization of immunotherapeutics, novel vaccines, and reliable, rapid, and affordable diagnostic platforms targeting neglected and underrepresented human viral infectious diseases including Ebola virus (EBOV) and Lassa virus (LASV). Zalgen technology and products strengthen global capabilities in biosafety, biosecurity and readiness for pathogen outbreaks (most importantly viral hemorrhagic fevers) and support medical countermeasure efforts directed to pandemic diseases and major epidemic-prone diseases.
In the past few years we and our collaborative partners achieved significant performance milestones including securing over $140 million in grant funding, developed and launched the first rapid diagnostic test for Lassa fever, developed and launched the first rapid test for Ebola viral disease to secure emergency use authorization from both the US FDA and the WHO, opened state of the art biotechnology facilities in Maryland and Colorado, published 24 scientific papers in peer-reviewed journals, and established the company as a premier provider of diagnostics, research reagents, and product development solutions for high consequence neglected tropical viral diseases.
In 2020, in response to the global SARS CoV-2 pandemic, we quickly broadened our focus and began development a battery of diagnostic tests, the first of which has been submitted to the FDA for emergency use authorization request.
At Zalgen we are dedicated to making a meaningful difference in developing and deploying medical countermeasures against neglected tropical diseases. Since our inception, we and our academic, government, biotechnology industry and healthcare provider partners have made significant strides against Ebola, Lassa and other highly fatal hemorrhagic viral diseases faced in resource limited areas of the world desperate for resources to enhance scientific research and improve patient care.
Our teams have traveled frequently to Sierra Leone, Nigeria and other West African countries, often during disease outbreaks. Working with scientists and healthcare workers, Zalgen has made measurable advances in the science of viral hemorrhagic diseases to improve the lives of these severe at-risk populations, impacted by these diseases and associated mortality rates approaching or exceeding 70%, and even higher in pregnant women and children.
Our goal is to develop and make available the best, most widely trusted and effective diagnostics, vaccines and immunotherapeutics to make a meaningful difference against these endemic and epidemic diseases. With active and broadly disseminated vaccine programs, field deployable rapid diagnostic tests, and availability of affordable and safe immunotherapeutics, celebrations with young survivors will be the norm rather than just the fortunate few who survive these diseases.
(L-R) Dr. Robert Garry, Dr. Jessica Grove (Hartnett), Lassa fever survivor (with permission), and Dr. Luis Branco. Young survivor of severe Lassa fever at Kenema Government Hospital, Eastern Sierra Leone, 2010. The patient, with family permission, helped our team assemble the most comprehensive longitudinal study of a severe Lassa fever infection with positive outcome recorded to date.
Our scientific team, advisors and collaborators have the experience and know-how to navigate through this difficult environment in a very efficient manner that will bring to market numerous innovative and useful products critical to combat these fevers and related neglected tropical diseases.
Led by Dr. Robert F. Garry, Zalgen programs cover three important business areas — vaccines, immunotherapeutics and diagnostics — all utilizing proprietary recombinant technology and platform experience resulting in solutions addressing critical medical needs.
B.S. (1974) Indiana State University, Life Sciences
Ph.D. (1978) University of Texas at Austin, Microbiology
Postdoctoral Research (1978-82) University of Texas at Austin
Dr. Garry is the President of the Viral Hemorrhagic Fever Consortium (VHFC), a non-profit consortium of scientists developing countermeasures including diagnostics, immunotherapeutics and vaccines, against Lassa virus, Ebola and Marburg viruses and other high consequence pathogens. Dr. Garry serves in the Tulane University administration as Assistant Dean for Graduate Studies in Biomedical Sciences and is the founding Editor-in-Chief of Virology Journal.
B.S. (1995) University of Massachusetts at Amherst, Microbiology
Ph.D. (2010) Tulane University, Biomedical Sciences
In his 25+ years in the immunotherapeutic industry Dr. Branco has been directly involved in the development of numerous licensed antibody therapeutics, including MedImmune’s Synagis (Palivizumab), Human Genome Sciences’ (HGSI) Benlysta (Belimumab) and ABthrax (raxibacumab), as well as additional antibodies under clinical evaluation. He is a co-founder of Zalgen and is the patent holder of CHOLCelect, a unique mammalian cell-based biomanufacturing system which generates highly regulatory compliant NS0 stable cell lines.
B.S. (1990) San Jose State University, Immunology & Medical Microbiology
Ph.D. (2015) Tulane University, Biomedical Sciences
Dr. Boisen has over 25 years’ experience in IVD product development with expertise in rapid, point-of-care diagnostics for detection of infectious diseases and biowarfare agents. With a broad background in diagnostic methodology including Lateral Flow Immunoassay, ELISA, optical biosensors, and micro-array platforms that span manual, semi-automated, and fully automated operation, Dr. Boisen is the Site Manager for the Zalgen Advanced Diagnostics Technology Center in Aurora, CO.
B.S. (1982) Kiev State University, Organic Chemistry
M.S. (1983) Kiev State University, Chemistry
Ph.D. (1992) Institute of Molecular Biology and Genetics, Ukrainian Academy of Sciences
Postdoctoral Research (1993-1998) National Institutes of Health
Dr. Koval has over 30 years of experience in the fields of molecular and cellular biology. At Zalgen Labs, he is developing Lassa GPC MARMs and neutralization assays using the VSV-LASV-G virus system. In addition, he plays a leading role in development and manufacturing of novel LASV and EBOV vaccines based on a promising recombinant VSV platform. Prior to joining Zalgen, Dr. Koval executed and managed multiple projects at Lonza Walkersville. His major expertise led in developing and commercialization of products based on human primary cell systems including stem cells, genetically engineered human cell lines, and cell-based assays.
B.Sc. (1975) Sardar Patel University, Microbiology
M.Sc. (1978) Maharaja Sayajirao University, Microbiology
Ph.D. (1983) Queen Mary, University of London, Microbiology and Molecular Biology
Dr. Lathigra is involved in developing bispecific antibodies against LASV and EBOV as second and potentially 3rd generation therapeutics based on Arevirumab and EBOLA antibodies. At MedImmune he was also involved in engineering second generation derivatives of Synagis. Dr. Lathigra has over 30 years of experience in bacteriology and has worked on mycobacteria, Lyme disease, and organisms that cause otitis media. He made key contributions for the determination of the whole genome DNA sequence of Lyme disease causing bacteria which has led to expedited evaluation of potential vaccine candidates against Lyme disease. In his work with the US Army for 12 years, Dr. Lathigra worked with high impact BSL-3 category infectious disease agents Bacillus anthracis, Francisella tularensis and Yersinia pestis.
B.S. (1990) Pontificia Universidade Catolica de Minas Gerais, Brazil, Biology
M.S. (1993) Universidade Federal de Minas Gerais, BH- Brazil, Microbiology
Ph.D. (2011) Universidade Federal de Minas Gerais, BH-Brazil, Cell Biology
Also make changes: Dr. Gentz has 25+ years of experience with cell culture laboratories for mammalian, insect and primary cultures. Strong expertise in developing CHO/NS0 stable cell lines producing high levels of protein and antibody therapeutics suitable for commercial manufacturing. At Human Genome Sciences, successfully generated the stable cell line Belimumab®, FDA approved treatment for Lupus Erythematosus. At Medimmune she was also involved in generating NSO stable lines for the second-generation derivatives of Synagis, Palivizumab®. As a new member of the Zalgen’s team she will manage and oversee a cell culture laboratory fully dedicated to develop NS0/CHO stable cell lines for large scale production.
The Zalgen organization is committed to highly ethical and responsible behavior in all that we do as individuals and as a team. We have in place policies and procedures resulting in consistent quality of our work product and ensuring all members of our staff are treated with the high level of respect they deserve. New employees are selected, trained and expected to commit to this same high level of ethical behavior.
Zalgen Policies and Procedures include: Adherence to the Research Investigators’ Financial Conflict of Interest (“RIFCOI”) regulations. This includes “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought” (42 CFR Part 50, Subpart F), and “Responsible Prospective Contractors” (45 CFR Part 94).
Zalgen Labs is continuously seeking talented, highly committed people to join our organization. If you are interested in joining a fast-paced biotechnology business, we want to hear from you.
Germantown, Maryland — Headquarters & Biotechnology Center
Aurora, Colorado — Diagnostics Technology Center
Colorado – Research Associate, IVD Development Research Associate_Assay Dev 09292020
Send your resume in confidence to: Admin@zalgenlabs.com
Zalgen Labs has been and will continue to be an equal opportunity employer. The Company will continue to take steps to assure that recruitment, hiring, assignment, promotion, compensation and all other personnel decisions are made and administered without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, ancestry, age (forty and above unless defined more broadly under applicable state law), mental and/or physical disability, genetic information, veteran status, any military service or application for military service, marital status, creed (belief system), citizenship status or membership in any other category protected under state, federal or local law.
20271 Goldenrod Lane, Suite 2083
Germantown, MD 20876
Office: (833) 482-8833 ex: 2
International: (301) 720-0330
Fax: (301) 349-1194
12635 E. Montview Blvd, Suite 325
Aurora, CO 80045
Office: (833) 482-8833 ex: 1
International: (301) 720-0330
Fax: (720) 859-4110